Gene Panel Diagnosis for Pancreatic Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for pancreatic ductal adenocarcinoma (PDAC) lack effective biomarkers to differentiate between benign pancreatic lesions and cancerous tumors, leading to diagnostic uncertainty and delayed treatment, with limited ability to predict the malignant potential of precursor lesions.
Innovation Solution
A method utilizing panels of specific genes, including ECT2, AHNAK2, SERPINB5, TMPRSS4, POSTN, S100P, CEACAM5, GABRP, and CUZD1, to diagnose PDAC, determine its likelihood, and predict treatment response through gene expression analysis in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current imaging and histopathology methods are used for PDAC diagnosis, then diagnostic procedures can be performed, but diagnostic accuracy is insufficient to differentiate PDAC from benign pancreatic diseases
Solution Approach 1:
The invention transitions from imaging-based diagnosis to molecular expression-based diagnosis by measuring gene expression levels of specific biomarkers (CEA, CA19-9, S100P, etc.) in biological samples. This parameter change from physical imaging to molecular quantification enables accurate differentiation between PDAC and benign conditions, resolving the diagnostic accuracy problem.
Solution Approach 2:
The invention introduces gene expression profiles as intermediary biomarkers that mediate between the patient's pancreatic condition and the diagnostic conclusion. These molecular intermediaries (specific gene expressions) provide objective, quantifiable data that bridge the gap between ambiguous imaging findings and definitive diagnosis, eliminating diagnostic uncertainty.
2Measurement precision
If multiple EUS FNA biopsy procedures are performed to improve diagnosis, then sensitivity for PDAC identification improves, but diagnostic time and procedural complexity increase
Solution Approach 1:
The invention performs preliminary molecular analysis on the initial biopsy sample by measuring gene expression levels of PDAC-specific biomarkers. This preliminary molecular characterization allows immediate differentiation between malignant and benign conditions, eliminating the need for repeated biopsy procedures and reducing diagnostic time while maintaining high sensitivity.
Solution Approach 2:
The invention replaces repeated mechanical biopsy procedures with a single molecular expression analysis. Instead of performing multiple physical sampling procedures (EUS FNA), the method uses molecular biomarker detection on a single sample to achieve definitive diagnosis, substituting mechanical repetition with molecular information density.
3Reliability
If resection of precursor lesions is performed to prevent PDAC progression, then survival outcome improves, but surgical morbidity and mortality increase due to uncertain malignant potential
Solution Approach 1:
The invention changes the assessment parameter from macroscopic imaging features to molecular gene expression profiles when evaluating precursor lesions. By measuring specific biomarker expressions (CEA, CA19-9, S100P, etc.), the method provides accurate molecular characterization of malignant potential, enabling precise selection of which precursor lesions require resection, thereby improving survival outcomes while avoiding unnecessary surgeries.
Solution Approach 2:
The invention provides molecular feedback on the malignant potential of precursor lesions through gene expression analysis. This feedback mechanism informs clinical decision-making by quantifying the risk of progression to invasive cancer, allowing clinicians to balance the benefits of preventive resection against surgical risks based on objective molecular data rather than uncertain imaging findings.
Data Source
AI summary
The present disclosure relates to the identification of genes and gene combinations that are correlated with patients having or being predisposed to developing pancreatic ductal adenocarcinoma (PDAC). In some instances, methods herein utilize panels of 5 or 10 genes to accurately diagnose PDAC, determine the likelihood of developing PDAC, or determine the severity/stages of PDAC. These panels may be used in a molecular diagnostic test.